Drug intelligence / Profile preview

ANY003

Development stage: Preclinical
Lead developer: Anya Biopharm
Modality: Peptides
Administration: Oral

Overview

ANY003 is an oral peptide inhibitor of the tumor necrosis factor receptor (TNFR) currently in preclinical development by Anya Biopharm. Developed using the proprietary Mira/Je® platform for oral peptide delivery, ANY003 is designed to treat various inflammatory diseases by modulating TNF-mediated signaling pathways. The drug is currently in the lead optimization stage, aiming to provide an oral alternative to traditional injectable TNF-targeting biologics.

Other names: Novel TNFR inhibitor

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on ANY003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANY003.

Explore the full profile